Asahi Kasei Corporation AHKSF
10.35 USD -0.06 (-0.62%)
At closeOct 30, 2026, 4:00 PM EDT
10.35 Day range 10.35
7.60 52-week range 11.84
- YTD
- +16.29%
- 1 year
- +32.35%
- Market cap
- 13.80B
- EPS (ttm)
- 0.92
- P/E ratio
- 11.25
- YTD return
- +16.29%
- 1-year return
- +32.35%
- Volume
- 100
- Avg volume
- 510
- Open
- 10.35
- Previous close
- 10.42
- Day's range
- 10.35 – 10.35
- 52-week range
- 7.60 – 11.84
- Earnings date
- Nov 11, 2026
2Y +3.86 (+58.93%)
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.2004.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | 0.2004 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.1919 | 0.2443 | +0.05 | +27.31% |
| May 11, 2026 | Mar 31, 2026 | 0.1336 | 0.1773 | +0.04 | +32.71% |
| Feb 3, 2026 | Dec 31, 2025 | 0.2162 | 0.2554 | +0.04 | +18.13% |
| Nov 4, 2025 | Sep 30, 2025 | 0.2293 | 0.2317 | 0.00 | +1.05% |
| Jul 28, 2025 | Jun 30, 2025 | 0.1373 | 0.1002 | -0.04 | -27.02% |
News
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults 
US FDA approves Asahi Kasei's drug for persistent herpes infections 
Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements 
Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients 
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics 
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing 
Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design 
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy 
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries 
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
Your note
Sign in to keep a note on AHKSF — it syncs with the Stock Master app.